MODIFICATION OF CUPREDOXIN DERIVED PEPTIDES AND METHODS OF USE THEREOF
First Claim
1. An isolated peptide comprising a cupredoxin or a truncation of a cupredoxin that has a modified residue, and wherein the isolated peptide has at least one pharmacologic activity of a wild-type cupredoxin.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention provides modified cupredoxin derived peptides with pharmacologic activity that have improved pharmacokinetic properties, and methods to use them to treat mammals suffering from various conditions related to the pharmacologic activities. Modifications of the cupredoxin derived peptides include amino acid sequence variants and structural derivations that increase the plasma half-life of the peptide, increase the specific activity of the pharmacologic activity, decrease immunogenicity, and decrease the biotransformation of the peptides. The modified cupredoxin derived peptides can be used in methods to treat mammals for cancer, conditions related to inappropriate angiogenesis, viral and bacterial infections, and specifically HIV and malaria, conditions related to ephrin signaling, and to deliver cargo compounds, including diagnostic compounds, to cancer cell
20 Citations
63 Claims
- 1. An isolated peptide comprising a cupredoxin or a truncation of a cupredoxin that has a modified residue, and wherein the isolated peptide has at least one pharmacologic activity of a wild-type cupredoxin.
-
52. A method of enhancing a pharmcokinetic property of a cupredoxin comprising:
modifying one or more amino acid residues of the cupredoxin, wherein the modifying retains at least one pharmocologic activity of wild-type cupredoxin. - View Dependent Claims (53, 54, 55, 56, 57, 58, 59)
Specification